Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization

Mortezaee, K. and Shabeeb, D. and Musa, A.E. and Najafi, M. and Farhood, B. (2019) Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization. Current clinical pharmacology, 14 (1). pp. 41-53.

[img] Text
NajafiandFarhood2018-59-MS.pdf

Download (726kB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

BACKGROUND: Nowadays, ionizing radiation is used for several applications in medicine, industry, agriculture, and nuclear power generation. Besides the beneficial roles of ionizing radiation, there are some concerns about accidental exposure to radioactive sources. The threat posed by its use in terrorism is of global concern. Furthermore, there are several side effects to normal organs for patients who had undergone radiation treatment for cancer. Hence, the modulation of radiation response in normal tissues was one of the most important aims of radiobiology. Although, so far, several agents have been investigated for protection and mitigation of radiation injury. Agents such as amifostine may lead to severe toxicity, while others may interfere with radiation therapy outcomes as a result of tumor protection. Metformin is a natural agent that is well known as an antidiabetic drug. It has shown some antioxidant effects and enhances DNA repair capacity, thereby ameliorating cell death following exposure to radiation. Moreover, through targeting endogenous ROS production within cells, it can mitigate radiation injury. This could potentially make it an effective radiation countermeasure. In contrast to other radioprotectors, metformin has shown modulatory effects through induction of several genes such as AMPK, which suppresses reduction/ oxidation (redox) reactions, protects cells from accumulation of unrepaired DNA, and attenuates initiation of inflammation as well as fibrotic pathways. Interestingly, these properties of metformin can sensitize cancer cells to radiotherapy. CONCLUSION: In this article, we aimed to review the interesting properties of metformin such as radioprotection, radiomitigation and radiosensitization, which could make it an interesting adjuvant for clinical radiotherapy, as well as an interesting candidate for mitigation of radiation injury after a radiation disaster. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Item Type: Article
Additional Information: cited By 0
Subjects: Physiology
Medicine
Anatomy Morphology
Pathology
Divisions: Faculty of Para medicine > Department of Management Radiology and Medical Physics
Depositing User: ART . editor
Date Deposited: 22 Jun 2019 11:43
Last Modified: 22 Jun 2019 11:43
URI: http://eprints.kaums.ac.ir/id/eprint/4304

Actions (login required)

View Item View Item